EVIDENCE VS HYPE · VITAMIN D3 VS D2
The hype: Vitamin D3 is the only form worth taking; vitamin D2 does not work.
There is a real difference between these forms in how effectively they tend to raise the standard blood measure of vitamin D status. But that finding is often inflated into claims that D2 is useless or that D3 delivers superior energy, immunity and mood. The evidence needs a narrower reading.
The short answer
Vitamin D3 generally raises total blood 25-hydroxyvitamin D more effectively than an equivalent studied dose of D2. Both forms can increase vitamin D status. The comparative evidence is strongest for this blood marker, not for proving that D3 prevents more fractures or treats more symptoms than D2 in otherwise equivalent patients.
Why people believe it
D2 is called ergocalciferol and D3 is called cholecalciferol, also written colecalciferol in UK medicines information. They are different forms of the same vitamin family. Supplements may use different sources, preparations and doses, so a label saying “vitamin D” does not tell you everything about the product.
The usual status test measures total 25-hydroxyvitamin D, abbreviated 25(OH)D. “Total” matters because the body produces corresponding metabolites from D2 and D3. A measurement of only one component can be misleading when judging the response to the other form. The appropriate comparison asks what happens to the total, using comparable regimens and reliable assays.
What the evidence says
A contemporary review favours D3 for the blood marker
A systematic review published in 2024 included 20 comparative studies and found D3 more effective overall at raising total 25(OH)D. In 12 daily-dose comparisons using a particular laboratory method, the rise was on average 10.39 nmol/L lower with D2; the confidence interval was 6.16–14.62 nmol/L lower. Results varied between studies, and information about response modifiers was incomplete. Both forms increased their corresponding hydroxylated metabolites. Read the comparative review ↗
This supports a practical preference for D3 when the aim is efficiently raising the standard vitamin D status marker. It does not show that every person will have precisely that difference. Baseline status, regimen and individual characteristics influence the response. One review author was affiliated with a mushroom business, a relevant commercial context to consider alongside the methods and results.
A UK food-fortification trial supports the same direction
A 2017 double-blind trial enrolled 335 healthy South Asian and white European women aged 20–64. Participants consumed placebo or food or juice fortified with 15 micrograms daily of D2 or D3 for 12 winter weeks. D3 produced a greater rise in total 25(OH)D than D2 in both delivery vehicles. Read the UK trial ↗
The experiment is useful because it compared the forms at the same daily amount rather than contrasting an expensive high-dose D3 product with a low-dose D2 product. However, its endpoint was blood status, not fracture prevention or a broad wellbeing score. Its population and winter setting also limit automatic generalisation to every person.
D2 is not biologically inactive
A separate 2024 meta-analysis of D2 supplementation trials found that D2 increased total vitamin D status, while changing the relative contributions of D2- and D3-derived metabolites. Because this review studied D2 response rather than exclusively matched head-to-head comparisons, it should not be used to establish exact equivalence. It does contradict the claim that D2 cannot work at all. Read the D2 review ↗
A useful distinction is therefore “generally less effective for raising this marker at comparable studied doses,” not “a fake vitamin.” A prescribed formulation should be judged in the context of the dose, response and treatment plan, rather than dismissed because a product advert favours another form.
The limitations
A blood marker is a relevant intermediate outcome for managing vitamin D status. It is not the same as demonstrating a clinical advantage in every condition. A form that raises the marker more does not automatically improve energy or protect against respiratory infections more.
Comparative studies differ in dosing frequency, duration, starting levels and laboratory techniques. The average difference cannot establish the right replacement regimen for an individual with malabsorption, kidney disease or another treatment indication. Those circumstances can involve different medicines and monitoring, outside a simple supermarket choice.
Trials and reviews can include participants from overlapping study sets. A later review is valuable for synthesis but does not mean that all its results are new independent trials. Commercial involvement also warrants scrutiny without making a study's direction automatically true or false.
The practical success of either form depends on taking the intended dose consistently. A theoretically preferred form that is unsuitable for someone's dietary requirements or difficult to take may not be the best real-world option. The meaningful question is whether the product fits an evidence-based purpose and an appropriate regimen.
What this means for you
For a routine supplement, D3 is a reasonable default when it meets your needs, but the daily amount and suitability matter more than a dramatic premium label. A higher dose should not be assumed to be better simply because it contains D3.
If following a prescription, do not switch formulations or calculate an alternative treatment dose without advice. Clinicians may use specific preparations for specific situations. NHS colecalciferol information describes prevention and treatment regimens rather than a general instruction to maximise a blood result. NHS medicine information ↗
Check source information if vegan suitability matters: do not assume every D3 product is animal-derived or that every capsule is vegan. Verify the actual product label and excipients. A certification or claim should be traceable to the product rather than inferred from the ingredient name.
Keep the reason for supplementation clear. Our investigation of deficiency and bone health explains established uses. Our higher-dose review asks a separate question that a D3-versus-D2 blood-marker advantage cannot answer. The Vitamin D3 Evidence Hub brings the evidence and buying considerations together.
Research & Sources
- van den Heuvel et al. (2024): comparative systematic review of frequently dosed D2 and D3.
- Tripkovic et al. (2017): UK randomised food-fortification trial.
- D2 supplementation (2024): time- and dose-response meta-analysis.
- NHS: colecalciferol uses and treatment context.
Review information
Evidence reviewed: October 2026. Indexed reports and guidance were checked; abstracts are not presented as full-text assessments. Educational information, not a personal treatment plan. No product testing, certification verification or commercial endorsement was performed. Scientific verdicts are independent of commercial recommendations. Affiliate disclosure · Editorial methodology.